2 recruiting. 2 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 2 | Recruiting 2 |
| Phase 2 | 1 | Recruiting 1 |
Follow Tuberous Sclerosis: new trials by email Literature Review of Tuberous Sclerosis trials Research Report on Tuberous Sclerosis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Safety, Tolerability, and Pharmacokinetics of SVG103 (Paxalisib) in Focal Cortical Dysplasia Type II (FCD-II), Tuberous Sclerosis Complex (TSC) or Hemimegalencephaly (HME) SVG103 - Focal Cortical Dysplasia, Tuberous Sclerosis Complex (TSC) | Phase 1 / Phase 2 | Recruiting | Sovargen | 12 | 2026-07-14 | 2026-08-10 |
| Sapu003 in Advanced mTOR-sensitive Solid Tumors Sapu003, Exemestane 25 MG - Breast Cancer Metastatic, Renal Cell Carcinoma (RCC) | Phase 1 | Recruiting | SAPU NANO (US) LLC | 27 | 2025-12-15 | 2026-01-27 |
Carcinoma, Hepatocellular (1) · Carcinoma, Renal Cell (1) · Focal Cortical Dysplasia (1) · Hemimegalencephaly (1) · Neuroendocrine Tumors (1)
Congenital Abnormalities (2) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (2) · Genetic Diseases, Inborn (2) · Hamartoma (2) · Heredodegenerative Disorders, Nervous System (2) · Malformations of Cortical Development (2) · Malformations of Cortical Development, Group I (2) · Neoplasms (2) · Neoplasms, Multiple Primary (2) · Neoplastic Syndromes, Hereditary (2) · Nervous System Diseases (2) · Nervous System Malformations (2) · Neurocutaneous Syndromes (2) · Neurodegenerative Diseases (2) · Adenocarcinoma (1)
Everolimus (1) · Injections (1) · exemestane (1)
SAPU NANO (US) LLC (1) · Sovargen (1)
Australia (2)